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ABSTRACT
Allergic diseases, such as atopic rhinitis, bronchial
asthma and urticaria, are prevalent and increasing in
frequency. Mast cells are known to play a central role
in the immediate phase reaction of allergic diseases
through the IgE-mediated release of a variety of chem-
ical mediators, such as histamine, leukotrienes and
prostaglandins. In contrast, T lymphocytes, basophils
and eosinophils are thought to be responsible for
inducing the late phase response. However, whether
the mast cell can be simplistically assigned a role in the
immediate phase allergic response and whether mast
cells are necessary for the ongoing allergic response,
including the development of hyperresponsiveness,
remains to be completely studied. In the present
article, the author will discuss the integrated roles of
mast cells in IgE-mediated allergic inflammation, with
specific emphasis on the roles of mast cell-derived
cytokines in the late phase allergic response and
chronic allergic inflammation.
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INTRODUCTION
The chain of events that leads to a type I allergic reaction
includes the recognition of allergen by the antigen-pre-
senting cells (APC), antigen presentation to T cells,
activation of T cells resulting in the production and
release of cytokines, such as interleukin (IL)-4 and IL-13,
class switching of IgM+ B cells to IgE+ plasma cells, the
production of IgE, binding of IgE to the high-affinity IgE
receptor (Fce RI) on the surface of mast cells and the
cross-linking of the bound IgE–Fce RI complex with multi-
valent allergen on subsequent exposure to the allergen,
resulting in the release of inflammatory mediators, such
as histamine, leukotrienes (LT) and prostaglandins.1–3
However, the allergic reaction in a type I allergic disease,
such as allergic rhinitis or atopic asthma, is comprised of
two phases, an immediate phase reaction and a late
phase allergic reaction. The immediate phase allergic
reaction occurs as a result of cross-linking of the aller-
gen-specific IgE, bound to the IgE receptor on the surface
of mast cells, to allergen, resulting in the release of chem-
ical mediators, such as histamine, LT and prostaglandin.
By contrast, the late phase allergic reaction is largely
inflammatory, occurring as a result of the inflammatory
mediators released by the infiltrated cells. Thus, it is well
known that mast cells play a central role in the immediate
phase allergic reaction, whereas other cells, such as T
cells, eosinophils and basophils, have been considered to
play important roles in the late phase allergic reaction.4–7
However, the question now is not just which of these
effector cells have more important roles in allergic
inflammation, but what exactly each of these cells do to
perpetuate allergic inflammation and, in situations where
their functions overlap, what the relative contribution of
each cell type is to allergic inflammatory responses. Still,
after decades of extensive study on the biology of these
effector cell types, the complete spectrum of their roles in
allergic inflammation remains to be defined. This is espe-
cially true with regard to the mast cell, where, despite
important observations on the biology of mast cells and a
variety of interesting hypotheses, the complete role of the
mast cell in allergic inflammation is not yet well defined.
The purpose of the present review is not to discuss all of
the roles of each effector cell in allergic disease. Instead,
taking perennial allergic rhinitis (PAR) as a prototype of a
type I allergic disease, I will discuss some of the shock
organ-specific characteristics and roles of mast cells in
allergic inflammation, thereby drawing a link between the
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biology of these cells and the clinical expression of aller-
gic disease.
Clinically, PAR is characterized by repeated attacks of
sneezing, runny nose (rhinorrhea) and blockage of the
nose (nasal obstruction). These typical symptoms are
observed throughout the year and the most common
cause of PAR is the house dust mite. This disease is
observed even in childhood and is more common in
those with a family history of atopic disease. These
patients are diagnosed on the basis of the above-
mentioned typical symptoms, anterior rhinoscopic find-
ings of a pale, boggy nasal mucosa, often with
hypertrophy of the turbinates and a watery nasal dis-
charge, a positive radioallergosorbent test (RAST),
positive skin and nasal provocation tests, as well as nasal
eosinophilia (by nasal smear examination).
The immediate phase allergic reaction or the early
phase response occurs within several seconds of
encounter with antigen and occurs as a result of cross-
linking of the bound allergen-specific IgE by allergen,
resulting in the release of histamine, LT and prostaglandin
and is clinically characterized by sneezing, rhinorrhea and
nasal obstruction. Sneezing results from the action of 
histamine on H1 receptors, present on the sensory nerve
endings of the trigeminal nerve in the subepithelium of
the nasal mucosa. Of particular importance is the action
of histamine on the subepithelial blood vessels, causing
vasodilatation, hyperemia and mucosal edema (Fig. 1).
These facts provide definite evidence that the mast cell is
the central cell involved in the type I allergic reaction.
In contrast, the late phase allergic reaction occurs
several hours after the early phase response (4–6 h), with
a recurrence of symptoms that lasts for about 18–24 h.
The late phase response is characterized by prolongation
of symptoms, such as occasional sneezing, rhinorrhea
and, most predominantly, sustained nasal blockage.
Several in vivo studies have shown that the late phase
allergic reaction occurs as a result of cytokines released
from T lymphocytes, which induce the up-regulation of
adhesion molecules like vascular cell adhesion molecule
(VCAM)-1 and intercellular adhesion molecule (ICAM)-1
on endothelial cells. This results in the infiltration of
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Fig. 1 Mechanism of the type I allergic reaction in the nose. APC, antigen-presenting cell; MHC, major histocompatibility
complex; Ag, antigen; TCR, T cell receptor; IL, interleukin; Th, T helper cell; Ig, immunoglobulin; RANTES, regulated upon activa-
tion, normal T cell expressed and presumably secreted; TNF, tumor necrosis factor; VCAM, vascular cell adhesion molecule; ICAM,
intercellular adhesion molecule; VLA, very late antigen; PAF, platelet-activating factor; ECP, eosinophilic cationic protein; LTB4,
leukotriene B4; MBP, major basic protein.
eosinophils, basophils and T cells and the subsequent
release of a number of soluble products, such as
prostaglandins (PG), LT, platelet-activating factor (PAF),
eosinophil cationic protein (ECP), major basic protein
(MBP) and so on (Fig. 1).8–10 The physiological effects of
the newly synthesized LT, which may include LTC4, LTD4
and LTE4, are mediated by increasing vascular perme-
ability, vasodilatation and inducing mucus secretion.
Moreover, studies on the levels of mediators, such as 
histamine, PGD2 and tryptase, in nasal lavage fluid after
allergen challenge have implicated basophils, but not
mast cells, as the main histamine-containing cells
involved in the late phase (based on results that the levels
of histamine, but not PGD2, increase in late phase reac-
tion (LPR), because only mast cells and not basophils
contain PGD2).9,10 However, recent studies have demon-
strated that mast cells are a source of multifunctional
cytokines, suggesting that these cells may also play
important roles in the cell infiltration associated with the
late phase allergic reaction.11–13
PHENOTYPES AND DISTRIBUTION OF MAST CELLS
Since the discovery of the granule-laden mast cell
(Mastzellen) in 1879 by Paul Ehrlich,14 and the description
by Riley et al. about the presence of the preformed media-
tor, histamine, in the mast cell,15 much has been learnt
about its biochemical characteristics and functional prop-
erties. In 1966, Enerback first classified mast cells (in rats)
based on the morphology, size and density of granules as
well as their staining properties.16 Subsequently, Irani et al.
classified human mast cells into two phenotypically distinct
subpopulations, based on the type of neutral proteases
they express. Specifically, MC (T) mast cells contain only
tryptase and the MC (TC) mast cells contain chymase,
cathepsin G and carboxypeptidase in addition to tryptase.17
Tryptase is known to exert different functions, such as: (i)
cleavage of the bronchodilator peptides, factor VII,
peptide histidine-methionine and vasodilatator calcitonin
gene-related peptide; (ii) sensitization of bronchial smooth
muscle to contractile agents; (iii) a kallikrein-like activity;
(iv) cleavage of matrix; (v) a mitogenic activity for fibro-
blasts and epithelial cells; (vi) stimulation of release of the
granulocyte chemoattractant IL-8; and (vii) up-regulation
of ICAM-1 expression on epithelial cells. Chymase is
involved in the degradation of the neuropeptide neu-
rotensin and IL-4 and stimulation of secretion from gland
cells. Thus, it is now well known that mast cells have phe-
notypically distinct subpopulations and exhibit not only
species-specific but also site-specific heterogeneity.
Mast cells are derived from CD34+ hematopoietic
progenitor cells,18–20 which migrate to and undergo mat-
uration in the peripheral tissues. Interactions between the
tyrosine kinase receptor c-kit, which is expressed on the
surface of mast cells and their precursors, and the c-kit
ligand, stem cell factor (SCF), are essential for normal
mast cell development and survival.21 Stem cell factor is
expressed on the plasma membrane of a variety of struc-
tural cells, such as fibroblasts and vascular endothelial
cells, and the extracellular domain of SCF can be
released from these cells by proteolytic cleavage.21 In
fact, it is possible that the local levels of SCF may regulate
not only the numbers, but also the phenotypes of mast
cells in normal and inflammatory tissues and also con-
tribute to the striking alterations in the proportion of mast
cells observed in association with a variety of disease
processes.21–28 However, it is also likely that a complex
interplay of cytokines and growth factors other than SCF
may regulate the development and phenotypic character-
istics of human mast cells.
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Fig. 2 Intra-epithelial infiltration of mast cells in the allergic
nasal mucosa. (Arrows indicate the infiltrated mast cells in the
epithelium.)
In humans and many other mammalian species, the
numbers of mast cells in normal tissues exhibit consider-
able variation according to the anatomic site. Moreover,
the numbers of mast cells vary in association with the
underlying inflammatory or immunologic condition.21,23–28
For example, in the nasal epithelium of normal subjects,
mast cells are undetected (although mast cells are
detected in the lamina propria), but in patients with aller-
gic rhinitis there is an increase in the numbers of MC (T)
cells into the nasal epithelial compartment (Fig. 2).28
Whether these MC (T) cells are migrating mature mast
cells that normally reside in the lamina propria, but have
migrated under the influence of some specific stimuli, or
are newly differentiated mast cells from precursors that
reside in the nasal mucosa is not yet quite clear.
Furthermore, the selective migration/increase of MC (T)
cells is also of interest.
MAST CELLS AS A SOURCE OF MULTIFUNCTIONAL
CYTOKINES
Cytokines are a highly potent, biologically active,
diverse group of glycoproteins that are synthesized and
secreted by many cell types in response to their activa-
tion and can modulate both specific immune responses
and immunologically non-specific inflammation, through
their ability to alter the function or gene expression of the
responsive target cells. Allergic inflammation is char-
acterized by many cytokine-dependent processes,
including: (i) the induction of IgE synthesis (IL-4 and 
IL-13); (ii) eosinophil recruitment, development and 
survival (IL-3, IL-5, granulocyte–macrophage colony-
stimulating factor (GM-CSF), IL-16 and certain C-C
chemokines, such as regulated upon activation, normal
T cell expressed and presumably secreted (RANTES) 
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Fig. 3 Interleukin (IL)-13 (a,b) and IL-4 (c,d) expression in nasal mast cells (a,c) and c-kit+ cells (b,d) of a perennial allergic rhinitis
patient (double immunostaining).
and Eotaxin); (iii) recruitment of monocytes and T cells
(IL-16 and certain C-C chemokines, such as RANTES);
and (iv) basophil recruitment (tumor necrosis factor
(TNF)- a , IL-4) or enhanced mediator production (IL-3,
IL-4, the C-C chemokine macrophage inflammatory
protein (MIP)-1 a ).29 Moreover, cytokines promote aller-
gic inflammation by enhancing the recruitment of
leukocytes through the up-regulation of adhesion mole-
cules, such as P-selectin, E-selectin and VCAM-1, and
on vascular endothelial cells.29–31 Finally, cytokines can
also critically influence the development and perpetua-
tion of chronic allergic inflammation.
Mast cells represent a potential source of many
cytokines that may influence allergic inflammation and
the synthesis and release of these products can be
induced via IgE-dependent mechanisms.11–13,32 When
mouse mast cells are activated via the Fc e RI, they can
express increased levels of mRNA for a range of
cytokines (IL-1 a , IL-3, IL-4, IL-5, IL-6, GM-CSF, MIP-1a ,
MIP-1 b and several other C-C chemokines) and also
secrete substances with corresponding activities.21,32–35
In humans too, recent studies have clearly shown that
mast cells are a potential source of several cytokines,
including IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-13, TNF-a
and basic fibroblast growth factor.34 Bradding et al. first
reported the expression of IL-4, IL-5 and IL-6 in
bronchial mast cells of atopic asthmatics.11 It is well
known now that bronchial and nasal mast cells from
atopic asthmatics and allergic rhinitics are an important
source of the T helper (Th)2-type cytokines IL-4, IL-5, 
IL-6, and IL-13 (Fig. 3).11–13 We have recently demon-
strated that nasal mast cells from patients with PAR to
house dust mite can release the IL-4, IL-6 and IL-13 pro-
teins when stimulated by specific allergen (mite antigen)
and that the levels of secreted IL-13 are 10-fold more
than that of IL-4.36,37
However, it is also of interest that there is some 
heterogeneity in the cytokine expression between
subsets of mast cells, in that MC (T) mast cells preferen-
tially express IL-5, IL-6 and IL-7, whereas MC (TC) mast
cells preferentially express IL-4.37,38 Isolated skin mast
cells, which are nearly all MC (TC), express high levels
of IL-4 immunoreactivity, but almost no immunoreactiv-
ity for IL-5 or IL-6.38 Such differences in the distribution
of cytokine expression between subsets of mast cells,
even within the same target tissue, suggest a difference
in the capacity of mast cell subsets to produce various
cytokines and therefore a difference in their specific
roles in allergic inflammation.
THE IGE RECEPTOR AND REGULATION OF ITS
EXPRESSION IN MAST CELLS
Ishizaka and Tomioka first described the presence of IgE
receptors on mast cells and that these cells could be acti-
vated to degranulate when cell surface-bound IgE is
cross-linked by allergen. Therefore, the expression of the
high-affinity IgE receptor (Fce RI) in mast cells and
basophils is critical to the development of allergic dis-
eases. The Fce RI is a tetrameric structure, comprising an
a -subunit, a b -subunit and two disulfide-linked g -sub-
units.39–41 The extracellular portion of the Fce RIa chain
contains the entire IgE-binding site.42,43 The b -subunit is
considered to be largely within the cell membrane, span-
ning it four times so that both the amino- and carboxy-
termini are within the cytoplasm.44 The b - and g - subunits
are known to be involved in signal transduction.45–47
Studies in Fce RIa chain-deficient mice have demon-
strated the inability of these mice to exert allergen-
induced anaphylaxis, even with normal numbers of mast
cells.48 Several lines of evidence indicate that mast cells
or basophils must display the high-affinity IgE receptors
on their surface to be able to have significant IgE antigen-
specific effector function.
Previously, two groups have independently demon-
strated that the level of Fce RI expression on circulating
basophils of patients with atopic dermatitis exhibits a pos-
itive correlation with serum IgE.49,50 In our studies, we
have found no significant difference in the total number
of nasal mast cells between patients with atopic and non-
atopic rhinitis.37 In contrast, nasal mast cells from PAR
patients exhibit increased levels of Fce RI expression and
IgE binding ability compared with those from non-atopic
rhinitics (Fig. 4).37 Moreover, Fce RI expression in the
nasal mast cells (NMC) of PAR patients correlates well
with the levels of serum IgE.36 This is of considerable
interest, because Pastorello et al. have previously demon-
strated a strong positive correlation between the level of
serum IgE and clinical symptoms in symptomatic patients
with allergic rhinoconjunctivitis.51 More recently, several
researchers have shown that IgE itself can regulate Fce RI
expression in mast cells. In this context, it is also of great
significance that nasal mast cells from PAR patients
exhibit increased IgE-mediated mediator (histamine and
cytokine) release, indicating the clinical relevance of the
increased expression of Fce RI in the mast cells of atopics.
These findings may explain our earlier observations that
mast cells from allergic nasal polyps release significant
amounts of histamine when stimulated with anti-IgE,
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compared with those from non-allergic nasal polyps,
which fail to exhibit any IgE-mediated histamine release,
even after passive sensitization.52
Again, little has been known until recently about the
factors that regulate the expression of the IgE receptor 
in mast cells. Toru et al. first reported that IL-4 can up-
regulate expression of Fce RI in cord blood-derived 
cultured human mast cells (CBHCMC).53 Yamaguchi
et al.54 and Saito et al.55 have reported that IgE can up-
regulate Fce RI expression in mouse mast cells and
CBHCMC. However, there is species-specific hetero-
geneity in mast cells and also differences between
cultured cells and primary cells. In this context, our obser-
vations that nasal mast cells exhibit increased leveIs of
Fce RI expression and increased IgE-mediated mediator
release and that IL-4 up-regulates Fce RI expression in
nasal mast cells36,37 suggest an important autocrine
amplification mechanism involving the mast cell itself,
because mast cells can produce IL-4.
MAST CELLS AND IGE SYNTHESIS
Gauchet et al. first reported that, when cultured human
mast cells (HMC-1) were stimulated with PMA and Ca
ionophore and then co-cultured with purified B cells in
the presence of IL-4 and anti-CD40 L, these cultured
human mast cells could induce the synthesis of IgE in
vitro.56 However, HMC-1 cells do not express the high-
affinity IgE receptor and no evidence has existed as to
whether or not allergen- and IgE-mediated activation of
mast cells can induce IgE synthesis. Recently, we have
demonstrated that nasal mast cells from PAR patients not
only release sufficient amounts of IL-4 or IL-13 on stimu-
lation with specific mite antigen, but also express the
CD40 ligand (CD40L) and induce IgE synthesis in B
cells.36 Interestingly, the mast cell-induced IgE synthesis
was more IL-13 dependent,36 bringing us to our earlier
observations of a strong correlation between levels of 
IL-13 expression in the nasal mucosa of PAR patients and
levels of serum IgE.12 Again, while it is well known that
allergen-activated Th2 cells can produce IL-4 and IL-13
and induce IgE synthesis in B cells, the finding that mast
cells can induce IgE synthesis not only suggests novel
roles for mast cells in perpetuating chronic allergic
inflammation, but also suggests that IgE may be pro-
duced locally in the shock organ itself.
LOCAL IGE SYNTHESIS
As early as 1970, Tada and Ishizaka first reported the
existence of a significant number of IgE-positive cells in
the bronchial mucosa and nasal polyps of atopics.57
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Fig. 4 Immunoglobulin E
binding ability (a,b) and high-
affinity IgE receptor (Fce RI)
expression (c,d) in nasal mast
cells of chronic infective rhinitis
(a,c) and perennial allergic
rhinitis patients (b,d; by flow
cytometric analysis).
These researchers then proposed the concept of local IgE
synthesis in the relevant mucosa and attributed the lack of
a good correlation between skin tests and clinical symp-
toms to the local synthesis of IgE, pointing out that the
skin sensitivity did not, in reality, reflect the nasal/
bronchial reactivity or the extent of local inflammation.
Recently, the presence of mRNA for IgE in patients with
seasonal allergic rhinitis has been reported after in vivo
antigen challenge.58 However, it is possible that these IgE
mRNA+ B cells had infiltrated into the nasal mucosa after
allergen challenge, in vivo. In this context, we have
recently reported the up-regulation of mRNA expression
for IgE C epsilon chain in nasal biopsies after in vitro
challenge with mite antigen (Der fII), indicating that IgE
class switch can occur locally in the nasal mucosa itself
(Fig. 5).59 Then, the question of whether the nasal
mucosa is provided with sufficient numbers of B cells that
can synthesize IgE arises. In this context, one can refer to
earlier studies on the proportion of lymphocyte subsets in
the nasal mucosa that have shown B cells to comprise
approximately 20% of the total lymphocyte population in
the nasal mucosa of allergic rhinitics. Moreover, we and
others have shown an increase in the numbers of IgE+ B
cells in the nasal mucosa of allergic rhinitics (although
few in number).60 Thus, one could speculate that the
shock organ may play a crucial role in the synthesis of
specific IgE, whereas the total IgE may also have a sys-
temic contribution from the associated lymphoid follicles.
This would explain why the cellular and molecular
changes in the shock organ reflect the clinical expression
of allergic disease. In fact, in the diagnosis of allergic
rhinitis, nasal provocation tests are more reliable than the
skin tests.
ADHESION MOLECULE EXPRESSION IN MAST CELLS
In addition to cytokines, a number of cell-surface mole-
cules are involved in the recruitment of inflammatory cells
into specific sites of inflammation.61 Lymphocytes and
mast cells in the tissues are surrounded by other cells,
such as fibroblasts and mucosal cells, as well as extra-
cellular matrix (ECM) proteins (e.g. collagen, fibronectin
and laminin). Therefore, the interaction of these inflam-
matory cells with fibroblasts and ECM may be important
in the perpetuation of chronic inflammation. It has been
reported that b 1-integrins, such as very late antigen
(VLA)-4, VLA-5 and the vitronectin receptor integrin, are
involved in mast cell activation, up-regulation of cytokine
expression in mast cells and mast cell survival.62 Recently,
we have demonstrated an up-regulation of the expres-
sion of VLA-4 and VLA-5 in nasal mast cells from PAR
patients and that IgE-mediated activation of mast cells
induces the release of greater levels of IL-4, IL-13 and
TNF-a , when cultured on fibronectin.63 Thus, mast
cell–ECM interactions may contribute to the enhance-
ment of mast cell activation, especially when the levels of
IgE and antigen in the micro-environment are rather low.
This may explain, in part, the phenomenon of hypersensi-
tivity seen in patients with allergic rhinitis.
The molecules VCAM-1 and ICAM-1 are the counter-
receptors or ligands for b 1- and b 2- integrins,
respectively. A striking feature in allergic inflammation is
the selective accumulation of activated eosinophils and
basophils, without increased numbers of neutrophils. In
this context, one may refer to studies that demonstrated
that ICAM-1 expression in the nasal mucosa of allergic
rhinitics was not up-regulated after stimulation with
antigen; however, VCAM-1 was up-regulated at 24 h
after allergen challenge.64 Because VLA-4 is not
expressed by neutrophils, the selective up-regulation of
VCAM-1 in the nasal mucosa may result in the selective
accumulation of activated eosinophils, basophils and
lymphocytes, without increased numbers of neutrophils. It
is known that IL-4 and IL-13 can up-regulate VCAM-1
expression in endothelial cells. This indicates that mast
cells and lymphocytes may indirectly contribute to the
recruitment of eosinophils and basophils, through the IL-
4/IL-13-induced up-regulation of VCAM-1 expression in
the nasal mucosa.
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Fig. 5 In vitro up-regulation of mRNA expression for inter-
leukin (IL)-4, IL-13 and C epsilon chain of IgE in the nasal
mucosa of a perennial allergic rhinitis patient after stimulation
with mite antigen, examined by reverse transcriptase poly-
merase chain reaction. Lanes 1,3, unstimulated (controls);
lanes 2, 4, stimulated with Der fll.
INTEGRATED ROLES OF MAST CELLS IN
MODULATING IGE-MEDIATED ALLERGY
Immediate phase response
The immediate hypersensitivity reaction is the patho-
physiologic hallmark of allergic rhinitis, allergic asthma
and anaphylaxis and the central role of the mast cell in
the pathogenesis of these disorders is widely accepted
(Fig. 6). It is conventionally believed that mast cells,
when activated via the high-affinity IgE receptor, react by
undergoing several morphologic changes, including
swelling of the cytoplasmic granules and subsequent 
solubilization of their granule contents. Histamine,
tryptase, PGD2 and LTC4 are among the mast cell prod-
ucts that can be detected immediately after exposure to
allergens. Histamine induces vasodilatation, increased
vascular permeability and increased glandular secretion
in the ipsilateral as well as contralateral sides through
neural reflexes. Prostaglandins, such as PGD2, also
cause edema by vasodilatation and increased vascular
permeability.
Late phase response
The late phase allergic reaction occurs as a result of the
infiltration of a variety of inflammatory cells, such as
eosinophils, basophils and T cells, and the subsequent
release of a number of soluble products, such as PG, LT,
PAF, ECP, MBP and so on. Tissue eosinophilia is therefore
an important aspect of the late phase allergic reaction.
Mast cells can induce the infiltration of eosinophils not
only through the up-regulation of VCAM-1 (by TNF-a , 
IL-4 and IL-13) on endothelial cells, but also through
release of eosinophil-chemotactic factors, such as PAF
and LTB4. In addition, mast cells can also enhance eosino-
phil survival through the release of GM-CSF. Interestingly,
strong correlations have been reported to exist between
the numbers of IL-4+, IL-5+ and TNF-a + mast cells and the
number of tissue eosinophils in atopic asthma and allergic
rhinitis.11 In this context, we refer to the hypothesis of Galli
and others,21–23 who have proposed that a mast
cell–leukocyte cytokine cascade critically contributes to
the initiation and perpetuation of IgE-dependent allergic
inflammation in the airways and other sites. In particular,
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Fig. 6 Integrated roles of nasal mast cells modulating IgE-mediated allergy. APC, antigen-presenting cell; MHC, major histocom-
patibility complex; Ag, antigen; TCR, T cell receptor; IL, interleukin; Th, T helper cell; NMC, nasal mast cell; TNF, tumor necrosis
factor; VCAM, vascular cell adhesion molecule; VLA, very late antigen; Fce RI, high-affinity IgE receptor.
the activation of mast cells through Fce RI initiates the
response (in part through the release of TNF-a , IL-4, IL-
13 and other cytokines) that can influence the recruitment
and function of additional effector cells (Fig. 6). These
recruited cells then promote the further progression of the
inflammatory response by providing additional sources of
certain cytokines (that can also be produced by mast cells
stimulated by ongoing exposure to allergen), as well as
new sources of cytokines and other mediators that may
not be produced by mast cells.
Time kinetics of cytokine secretion from purified lung
mast cells have shown that on IgE-mediated stimulation,
mRNA expression for IL-13 is up-regulated within 2–4 h
and the protein secretion is detectable at 12 h and peaks
at 24–48 h.65 In addition, nasal mast cells from allergic
rhinitics release both IL-4 and IL-13 at 24–48 h.36 In fact,
in the presence of SCF, the ligation of cell-bound IgE
results in an increase in the transcription and production
of these cytokines in mast cells.66 Immunoelectron
microscopy has shown that these cytokines are located in
the mast cell secretory granules and are released on IgE-
dependent stimulation along with other preformed
mediators.11,67 Again, TNF-a is constitutively expressed 
in mast cells and can be released within 2 h of IgE-
mediated stimulation. In fact, Klien et al.68 have shown
that activation of mast cell products in fragments of
human skin in vitro results in the up-regulation of 
E-selectin expression in adjacent vascular endothelial
cells and this is attributed to the release of TNF-a .
Moreover, interaction of mast cells with extracellular
matrix further enhances the IgE-mediated cytokine
release from mast cells.63 Taken together, these studies
strongly suggest that the mast cell is a key effector cell in
the late phase reaction. In this context, I would like to
refer to the report that the late asthmatic response can be
inhibited by disodium cromoglycate (DSCG) and also by
b -agonists, such as salbutamol, all of which inhibit mast
cell degranulation following IgE-dependent activation,
indicating the important role of the mast cell in LPR.
CHRONIC ALLERGIC INFLAMMATION
Most recent studies suggest that the mast cell has the
potential to regulate allergic inflammation by inducing
IgE synthesis in B cells. Under allergic inflammatory con-
ditions, ‘primed’ mast cells express high levels of the
high-affinity receptor for IgE and the ligand for the
surface antigen CD40, which is involved in T/B cell inter-
actions leading to immunoglobulin production, as well as
the Th2-type cytokines IL-4 and IL-13.36 The critical role
of these cells in the induction of IgE synthesis is supported
by the findings that anti-ligand for the surface antigen
CD40, anti-IL-4 and anti-IL-13 monoclonal antibodies
inhibit IgE production.36 Mast cells also have the potential
to function as APC, with the ability to shift T cells into Th2
subtypes. These recent findings suggest that mast cells
can modulate important regulatory functions of the aller-
gic response by acting directly on B cells and inducing
IgE. Because it is almost undoubtedly known now that IgE
synthesis can occur locally in the nasal mucosa itself, it is
quite likely that the locally produced IgE can thereafter
up-regulate Fce RI expression in mast cells. The aug-
mented Fce RI in mast cells may contribute to the binding
of increased number of IgE–Ag complexes, which in turn
can enhance the sensitivity of mast cells to allergen,
resulting in the enhancement of the production of
immunomodulatory cytokines and chemical mediators
and forming an important positive-feedback amplifica-
tion loop involving the IgE–IgE receptor mast cell
cascade (Fig. 6).36,37
Finally, mast cell activation may directly or indirectly
promote the release of cytokines from other resident cells
in the respiratory tract, such as macrophages, epithelial
cells, vascular endothelial cells, fibroblasts, and nerves;
cytokines released in these responses then contribute to
the vascular and epithelial changes and to the angiogen-
esis that is so prominent. At certain points in the natural
history of these complex processes, cytokines derived
from mast cells (transforming growth factor (TGF)-b ),
eosinophils or other recruited cells may also contribute to
the down-regulation of the response.
POTENTIAL THERAPIES THAT TARGET THE
IGE–IGE RECEPTOR MAST CELL CASCADE
Glucocorticoids and cyclosporine are known to inhibit
cytokine production in many cell types. In mice, both glu-
cocorticoids and cyclosporine can diminish mast cell
cytokine production in vitro, and can also suppress mast
cell- and TNF-a -dependent allergic inflammation in
vivo.69,70 Immunotherapy has also been shown to reduce
the number of intra-epithelial mast cells in patients with
seasonal allergic rhinitis, in good correlation with the
clinical symptoms. However, the identification of key cells
and molecules involved in the initiation and maintenance
of allergic inflammation is likely to become an important
target in the treatment of allergic diseases. Although anti-
IgE monoclonal antibodies (mAbs) have always been
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used to trigger mediator release from basophils or mast
cells, non-anaphylactogenic antihuman IgE Ab are now
in clinical evaluation as a therapeutic agent against
atopic disease. One type of these new mAbs, which is
non-anaphylactogenic, recognizes receptor-bound IgE
and prevents the association of IgE with its receptor if
immune complexes are formed between IgE and anti-IgE
mAb.71 This can explain the phenomenon that addition of
anti-IgE Ab to receptor-bound IgE results in a decrease 
of receptor-bound IgE, because IgE dissociating from 
the receptor is complexed, altering the thermodynamic
balance of receptor-bound and free IgE.
CGP 51901 is another non-anaphylactogenic mouse/
human chimeric antihuman IgE antibody that binds to free
IgE and surface IgE of IgE-expressing B cells, but not to IgE
bound to high-affinity IgE receptors (Fce RI) on mast cells
and basophils or low-affinity IgE receptors (Fce RII) on
other cells.72 A phase 1 double-blind, placebo-controlled,
single-dose study with doses of 3, 10, 30, and 100 mg
CGP 51901 was conducted in 33 pollen-sensitive sub-
jects who had raised levels of serum IgE and received
either intravenous CGP 51901 or placebo.72 The admin-
istration of CGP 51901 was well tolerated and resulted in
a decrease of serum-free IgE levels in a dose-dependent
manner, with suppression after 100 mg of CGP 51901
reaching > 96%. The time of recovery to 50% of baseline
IgE correlated with the dose of administered antibody.
Another group of researchers have recently studied the
expression of IgE and Fce RI on human basophils of 15
subjects receiving humanized anti-IgE mAb intravenously.73
Treatment with the anti-IgE mAb decreased free IgE 
levels to 1% of pretreatment levels and also resulted in a
marked down-regulation of Fce RI on basophils. The
responsiveness of the cells to IgE-mediated stimulation
using anti-IgE Ab was marginally decreased (approxi-
mately 40%), while the response of the same cells to
stimulation with dust mite Ag, Dermatophagoides
farinae, was reduced by approximately 90%. As also indi-
cated in our studies and those of others, one possible
explanation for these results is that Fce RI density is directly
regulated by plasma-free IgE levels. Thus, the increased
level of Fce RI expression in NMC from PAR patients that is
associated with an increase in mediator release on cross-
linking of the receptor may be very effectively down-
regulated by the use of anti-IgE mAb.
CONCLUSION
It has been suggested that allergic airway inflammation
results from a failure in the normal capacity to control
otherwise harmful IgE-mediated immune responses. In
the present review, it is suggested that an alternative
pathogenetic mechanism is operating in atopic patients
with asthma or rhinitis. In addition to a genetic predispo-
sition towards an exaggerated defensive IgE response to
inhaled allergens, there may be an up-regulated Fce RI
expression in mast cells. Indeed, while the present brief
review has emphasized the roles of mast cells in modulat-
ing allergic inflammation, the redundancy in the effector
mechanisms that potentially participate in allergic inflam-
mation is considerable. Many cells express several
cytokines, several mediators, the Fce RI and/or CD23 and
thus have overlapping functions. At the same time, the
possibility that some of the cells and mediators that par-
ticipate in the allergic responses may help to down-
regulate the allergic response cannot be ruled out. Even
cytokines that have pro-inflammatory effects may have
anti-inflammatory effects at certain points in time. In this
context, TGF-b from mast cells and eosinophils may play
an important role in down-regulating the allergic
response. Thus, the delicate balance in directing an
effector cell to act in a particular direction (inflammatory
or anti-inflammatory) is vital to the development of clini-
cal disease. In conclusion, we have highlighted recent
evidence that mast cells play more diverse and crucial
roles as both effector and immunoregulatory cells in per-
petuating allergic inflammation. Future management of
allergic airway diseases should take into account mast
cells as potential targets for anti-allergy therapy targeting
the IgE–Fce RI-mast cell cascade.
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